In vitro evaluation of PHISIO-coated sets for pediatric cardiac surgery

References

• Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1983; 86: 845–57
   PubMed Web of Science ®Google Scholar
• Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 2003; 75: S715–S720
   PubMed Web of Science ®Google Scholar
• Moen O, Fosse E, Braten J, Andersson C, Hogasen K, Mollnes TE, et al. Differences in blood activation related to roller/centrifugal pumps and heparin-coated/uncoated surfaces in a cardiopulmonary bypass model circuit. Perfusion. 1996; 11: 113–23
   PubMed Web of Science ®Google Scholar
• Fosse E, Mollnes TE, Ingvaldsen B. Complement activation during major operations with or without cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1987; 93: 860–6
   PubMed Web of Science ®Google Scholar
• Fiane AE, Videm V, Lingaas PS, Heggelund L, Nielsen EW, Geiran OR, et al. Mechanism of complement activation and its role in the inflammatory response after thoracoabdominal aortic aneurysm repair. Circulation. 2003; 108: 849–56
   PubMed Web of Science ®Google Scholar
• Larmann J, Theilmeier G. Inflammatory response to cardiac surgery: Cardiopulmonary bypass versus non-cardiopulmonary bypass surgery. Best Pract Res Clin Anaesthesiol. 2004; 18: 425–38
   PubMedGoogle Scholar
• Brix-Christensen V. The systemic inflammatory response after cardiac surgery with cardiopulmonary bypass in children. Acta Anaesthesiol Scand. 2001; 45: 671–9
   PubMed Web of Science ®Google Scholar
• Grossi EA, Kallenbach K, Chau S, Derivaux CC, Aguinaga MG, Steinberg BM, et al. Impact of heparin bonding on pediatric cardiopulmonary bypass: A prospective randomized study. Ann Thorac Surg. 2000; 70: 191–6
   PubMed Web of Science ®Google Scholar
• Saatvedt K, Lindberg H, Geiran OR, Michelsen S, Aasen AO, Pedersen T, et al. Complement activation and release of tumour necrosis factor alpha, interleukin-2, interleukin-6 and soluble tumour necrosis factor and interleukin-2 receptors during and after cardiopulmonary bypass in children. Scand J Clin Lab Invest. 1995; 55: 79–86
   PubMed Web of Science ®Google Scholar
• Seghaye MC, Duchateau J, Grabitz RG, Faymonville ML, Messmer BJ, Buro-Rathsmann K, et al. Complement activation during cardiopulmonary bypass in infants and children. Relation to postoperative multiple system organ failure. J Thorac Cardiovasc Surg. 1993; 106: 978–87
   PubMed Web of Science ®Google Scholar
• Heying R, van OW, Wilhelm S, Schumacher K, Grabitz RG, Messmer BJ, et al. Children undergoing cardiac surgery for complex cardiac defects show imbalance between pro- and anti-thrombotic activity. Crit Care. 2006; 10: R165
   PubMedGoogle Scholar
• T+írnok A, Hambsch J, Emmrich F, Sack U, van Son J, Bellinghausen W, et al. Complement activation, cytokines, and adhesion molecules in children undergoing cardiac surgery with or without cardiopulmonary bypass. Pediatr Cardiol. 1999; 20: 113–25
   PubMed Web of Science ®Google Scholar
• Paparella D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: Pathophysiology and treatment. An update. Eur J Cardiothorac Surg. 2002; 21: 232–44
   PubMed Web of Science ®Google Scholar
• Rubens FD, Mesana T. The inflammatory response to cardiopulmonary bypass: A therapeutic overview. Perfusion. 2004; 19(Suppl 1)S5–S12
   PubMedGoogle Scholar
• Fosse E, Thelin S, Svennevig JL, Jansen P, Mollnes TE, Hack E, et al. Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes: A European multicentre study. Eur J Cardiothorac Surg. 1997; 11: 320–7
   PubMed Web of Science ®Google Scholar
• Videm V, Mollnes TE, Fosse E, Mohr B, Bergh K, Hagve TA, et al. Heparin-coated cardiopulmonary bypass equipment. I. Biocompatibility markers and development of complications in a high-risk population. J Thorac Cardiovasc Surg. 1999; 117: 794–802
   PubMed Web of Science ®Google Scholar
• Ovrum E, Mollnes TE, Fosse E, Holen EA, Tangen G, Ringdal MA, et al. High and low heparin dose with heparin-coated cardiopulmonary bypass: Activation of complement and granulocytes. Ann Thorac Surg. 1995; 60: 1755–61
   PubMed Web of Science ®Google Scholar
• Svenmarker S, Haggmark S, Jansson E, Lindholm R, Appelblad M, Sandstrom E, et al. Use of heparin-bonded circuits in cardiopulmonary bypass improves clinical outcome. Scand Cardiovasc J. 2002; 36: 241–6
   PubMed Web of Science ®Google Scholar
• Ovrum E, Tangen G, Tollofsrud S, Ringdal MA. Heparin-coated circuits and reduced systemic anticoagulation applied to 2500 consecutive first-time coronary artery bypass grafting procedures. Ann Thorac Surg. 2003; 76: 1144–8
   PubMed Web of Science ®Google Scholar
• Schreurs HH, Wijers MJ, Gu YJ, van OW, van Domburg RT, de Boer JH, et al. Heparin-coated bypass circuits: Effects on inflammatory response in pediatric cardiac operations. Ann Thorac Surg. 1998; 66: 166–71
   PubMed Web of Science ®Google Scholar
• Jensen E, Andreasson S, Bengtsson A, Berggren H, Ekroth R, Lindholm L, et al. Influence of two different perfusion systems on inflammatory response in pediatric heart surgery. Ann Thorac Surg. 2003; 75: 919–25
   PubMed Web of Science ®Google Scholar
• Jensen E, Andreasson S, Bengtsson A, Berggren H, Ekroth R, Larsson LE, et al. Changes in hemostasis during pediatric heart surgery: Impact of a biocompatible heparin-coated perfusion system. Ann Thorac Surg. 2004; 77: 962–7
   PubMed Web of Science ®Google Scholar
• Olsson C, Siegbahn A, Henze A, Nilsson B, Venge P, Joachimsson PO, et al. Heparin-coated cardiopulmonary bypass circuits reduce circulating complement factors and interleukin-6 in paediatric heart surgery. Scand Cardiovasc J. 2000; 34: 33–40
   PubMed Web of Science ®Google Scholar
• Hayward JA, Chapman D. Biomembrane surfaces as models for polymer design: The potential for haemocompatibility. Biomaterials 1984; 5: 135–42
   PubMed Web of Science ®Google Scholar
• De SF, Francois K, van OW, Poelaert J, De WD, Ebels T, et al. Phosphorylcholine coating of extracorporeal circuits provides natural protection against blood activation by the material surface. Eur J Cardiothorac Surg. 2000; 18: 602–6
   PubMed Web of Science ®Google Scholar
• Draaisma AM, Hazekamp MG, Anes N, Schoof PH, Hack CE, Sturk A, et al. Phosphorylcholine coating of bypass systems used for young infants does not attenuate the inflammatory response. Ann Thorac Surg. 2006; 81: 1455–9
   PubMed Web of Science ®Google Scholar
• Videm V, Nilsson L, Venge P, Svennevig JL. Reduced granulocyte activation with a heparin-coated device in an in vitro model of cardiopulmonary bypass. Artif Organs 1991; 15: 90–5
   PubMed Web of Science ®Google Scholar
• Mollnes TE, Lea T, Harboe M. Detection and quantification of the terminal C5b-9 complex of human complement by a sensitive enzyme-linked immunosorbent assay. Scand J Immunol. 1984; 20: 157–66
   PubMed Web of Science ®Google Scholar
• Mollnes TE, Videm V, Riesenfeld J, Garred P, Svennevig JL, Fosse E, et al. Complement activation and bioincompatibility. The terminal complement complex for evaluation and surface modification with heparin for improvement of biomaterials. Clin Exp Immunol. 1991; 86(Suppl 1)21–6
   PubMedGoogle Scholar
• Wagner JL, Hugli TE. Radioimmunoassay for anaphylatoxins: A sensitive method for determining complement activation products in biological fluids. Anal Biochem. 1984; 136: 75–88
   PubMed Web of Science ®Google Scholar
• Mollnes TE, Videm V, Christiansen D, Bergseth G, Riesenfeld J, Hovig T. Platelet compatibility of an artificial surface modified with functionally active heparin. Thromb Haemost. 1999; 82: 1132–6
   PubMed Web of Science ®Google Scholar
• De SF, Van BY, Caes F, Francois K, Arnout J, Bossuyt X, et al. Phosphorylcholine coating offers natural platelet preservation during cardiopulmonary bypass. Perfusion. 2002; 17: 39–44
   PubMed Web of Science ®Google Scholar
• Hoel TN, Videm V, Baksaas ST, Mollnes TE, Brosstad F, Svennevig JL. Comparison of a Duraflo II-coated cardiopulmonary bypass circuit and a trillium-coated oxygenator during open-heart surgery. Perfusion. 2004; 19: 177–84
   PubMed Web of Science ®Google Scholar
• Baksaas ST, Videm V, Pedersen T, Karlsen H, Mollnes TE, Brosstad F, et al. Comparison of three oxygenator-coated and one total-circuit-coated extracorporeal devices. Perfusion. 1999; 14: 119–27
   PubMed Web of Science ®Google Scholar
• Ovrum E, Mollnes TE, Fosse E, Holen EA, Tangen G, Abdelnoor M, et al. Complement and granulocyte activation in two different types of heparinized extracorporeal circuits. J Thorac Cardiovasc Surg. 1995; 110: 1623–32
   PubMed Web of Science ®Google Scholar
• Raja SG, Berg GA. Impact of off-pump coronary artery bypass surgery on systemic inflammation: Current best available evidence. J Card Surg. 2007; 22: 445–55
   PubMed Web of Science ®Google Scholar
• Lappegard KT, Fung M, Bergseth G, Riesenfeld J, Lambris JD, Videm V, et al. Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation. Ann Thorac Surg. 2004; 77: 932–41
   PubMed Web of Science ®Google Scholar
• Baksaas ST, Videm V, Fosse E, Karlsen H, Pedersen T, Mollnes TE, et al. In vitro evaluation of new surface coatings for extracorporeal circulation. Perfusion. 1999; 14: 11–9
   PubMed Web of Science ®Google Scholar
• Lappegard KT, Fung M, Bergseth G, Riesenfeld J, Mollnes TE. Artificial surface-induced cytokine synthesis: Effect of heparin coating and complement inhibition. Ann Thorac Surg. 2004; 78: 38–44
   PubMed Web of Science ®Google Scholar
• Lappegard KT, Bergseth G, Riesenfeld J, Sexton J, Mollnes TE. Role of granulocytes and monocytes in the polyvinyl chloride-induced synthesis of interleukin 8, monocyte chemoattractant protein 1, and leukotriene B4. J Biomed Mater Res A. 2005; 74: 230–6
   PubMedGoogle Scholar
• Moen O, Fosse E, Braten J, Andersson C, Fagerhol MK, Venge P, et al. Roller and centrifugal pumps compared in vitro with regard to haemolysis, granulocyte and complement activation. Perfusion. 1994; 9: 109–17
   PubMedGoogle Scholar